Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$110.31 - $140.45 $17.2 Million - $22 Million
156,300 Added 598.85%
182,400 $20.7 Million
Q1 2024

May 15, 2024

SELL
$114.22 - $140.1 $6.81 Million - $8.35 Million
-59,600 Reduced 69.54%
26,100 $3.62 Million
Q4 2023

Feb 14, 2024

SELL
$75.49 - $124.16 $3.99 Million - $6.56 Million
-52,800 Reduced 38.12%
85,700 $10.6 Million
Q2 2023

Aug 14, 2023

BUY
$112.47 - $130.98 $15.6 Million - $18.1 Million
138,500 New
138,500 $17.8 Million
Q4 2022

Feb 10, 2023

SELL
$84.98 - $122.67 $1.71 Million - $2.47 Million
-20,100 Reduced 99.01%
200 $22,000
Q3 2022

Nov 14, 2022

SELL
$76.35 - $94.18 $595,530 - $734,604
-7,800 Reduced 27.76%
20,300 $1.64 Million
Q2 2022

Aug 12, 2022

BUY
$67.99 - $132.89 $1.44 Million - $2.82 Million
21,200 Added 307.25%
28,100 $2.09 Million
Q3 2021

Nov 15, 2021

BUY
$106.71 - $143.18 $736,299 - $987,942
6,900 New
6,900 $3.77 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $26.1B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.